相似文献
1
Evolving progress in the management of malignant plasma cell disorders.
Cancer Treat Res Commun. 2022;32:100612. doi: 10.1016/j.ctarc.2022.100612. Epub 2022 Jul 19.
2
Acute leukemia evolving from multiple myeloma and co-expressing myeloid and plasma cell antigens.
Am J Hematol. 1990 Jul;34(3):210-4. doi: 10.1002/ajh.2830340311.
3
Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders.
Cancer Treat Res. 2009;144:317-55. doi: 10.1007/978-0-387-78580-6_14.
4
Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.
Br J Haematol. 1998 Sep;102(4):1069-80. doi: 10.1046/j.1365-2141.1998.00880.x.
5
Plasma Cell Disorders.
Prim Care. 2016 Dec;43(4):677-691. doi: 10.1016/j.pop.2016.07.002. Epub 2016 Oct 14.
6
Carcinoma coexistent with malignant disorders of plasma cells; an autopsy survey.
Cancer. 1958 May-Jun;11(3):546-9. doi: 10.1002/1097-0142(195805/06)11:3<546::aid-cncr2820110315>3.0.co;2-s.
7
[Research Progress on Multiple Myeloma with Extramedullary Disease].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Jun;24(3):945-8. doi: 10.7534/j.issn.1009-2137.2016.03.057.
8
The incidence of phagocytizing plasma cells in malignant plasma cell dyscrasias.
Scand J Haematol. 1986 May;36(5):480-3. doi: 10.1111/j.1600-0609.1986.tb02284.x.
9
Intrapleural cisplatin for management of malignant pleural effusion in a patient with plasma cell leucaemia.
BMJ Case Rep. 2015 Jun 29;2015:bcr2015210044. doi: 10.1136/bcr-2015-210044.
10
Progress in the Treatment of Primary Plasma Cell Leukemia.
J Clin Oncol. 2016 Jun 20;34(18):2082-4. doi: 10.1200/JCO.2016.66.6115. Epub 2016 Apr 25.
本文引用的文献
1
Aging-associated immune system changes in multiple myeloma: The dark side of the moon.
Cancer Treat Res Commun. 2021;29:100494. doi: 10.1016/j.ctarc.2021.100494. Epub 2021 Nov 20.
2
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States.
Leukemia. 2022 Mar;36(3):801-808. doi: 10.1038/s41375-021-01453-5. Epub 2021 Oct 26.
3
Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma.
Cancer Treat Res Commun. 2021;29:100473. doi: 10.1016/j.ctarc.2021.100473. Epub 2021 Oct 9.
4
Supportive care in multiple myeloma: Current practices and advances.
Cancer Treat Res Commun. 2021;29:100476. doi: 10.1016/j.ctarc.2021.100476. Epub 2021 Oct 9.
5
Immunotherapy in multiple myeloma.
Cancer Treat Res Commun. 2021;29:100468. doi: 10.1016/j.ctarc.2021.100468. Epub 2021 Oct 2.
6
Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma.
Cancer Treat Res Commun. 2021;29:100444. doi: 10.1016/j.ctarc.2021.100444. Epub 2021 Aug 4.
7
Practical management and assessment of primary plasma cell leukemia in the novel agent era.
Cancer Treat Res Commun. 2021;28:100414. doi: 10.1016/j.ctarc.2021.100414. Epub 2021 Jun 8.
8
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials.
Am J Hematol. 2021 Sep 1;96(9):1131-1136. doi: 10.1002/ajh.26269. Epub 2021 Jul 5.
9
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
10
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.
Am J Hematol. 2020 May;95(5):548-567. doi: 10.1002/ajh.25791.
Zotero 插件